Viridian Therapeutics, Inc.
VRDN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001590750
In the last 90 days, Viridian Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 214 institutions reported holding it in 13F filings for Q2 2026, worth $2.50B in total; no superinvestor holds it.
13F holders, Q3 2022
Institutional positions in Viridian Therapeutics, Inc. as of Sep 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 105
- +21 vs. Q2 2022
- Shares held
- 38.0M
- +9.64M (+34.1%) vs. Q2 2022
- Total value
- $778.5M
- +$450.8M (+137.6%) vs. Q2 2022
- New holders
- 31
- 51 more added
- Sold out
- 10
- 14 more reduced
Compare with Q2 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting VRDN on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 214 | $2.50B |
| Q1 2026 | 225 | $2.21B |
| Q4 2025 | 229 | $3.36B |
| Q3 2025 | 169 | $2.01B |
| Q2 2025 | 171 | $1.32B |
| Q1 2025 | 177 | $1.23B |
| Q4 2024 | 179 | $1.75B |
| Q3 2024 | 165 | $1.98B |
| Q2 2024 | 138 | $906.2M |
| Q1 2024 | 136 | $1.24B |
| Q4 2023 | 132 | $1.31B |
| Q3 2023 | 124 | $769.9M |
| Q2 2023 | 128 | $1.12B |
| Q1 2023 | 135 | $1.10B |
| Q4 2022 | 122 | $1.21B |
| Q3 2022 | 105 | $778.5M |
| Q2 2022 | 84 | $327.7M |
| Q1 2022 | 72 | $460.9M |
| Q4 2021 | 55 | $459.8M |
| Q3 2021 | 39 | $223.7M |
| Q2 2021 | 26 | $109.8M |
| Q1 2021 | 33 | $84.5M |
Institutions, Q3 2022
Shares, value and share of portfolio for each institution holding Viridian Therapeutics, Inc.; share changes are against Q2 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 1,856,800 | $38.1M | 0.00% | +445,898+31.6% | Added |
| Deep Track Capital, LP | 1,970,290 | $40.4M | 2.00% | +800,000+68.4% | Added |
| BlackRock Inc. | 1,982,062 | $40.7M | 0.00% | +559,238+39.3% | Added |
| VR Adviser, LLC | 2,130,308 | $43.7M | 6.74% | +277,389+15.0% | Added |
| Commodore Capital LP | 2,696,340 | $55.3M | 8.89% | +1,057,731+64.6% | Added |
| Frazier Life Sciences Management, L.P. | 0 | $0 | 0.00% | −980,302−100.0% | Sold out |
| Ally Bridge Group (NY) LLC | 0 | $0 | 0.00% | −496,012−100.0% | Sold out |
| Franklin Resources Inc | 0 | $0 | 0.00% | −250,000−100.0% | Sold out |
| Bridger Management, LLC | 0 | $0 | 0.00% | −66,300−100.0% | Sold out |
| Alliancebernstein L.P. | 0 | $0 | 0.00% | −50,479−100.0% | Sold out |
| Affinity Asset Advisors, LLC | 0 | $0 | 0.00% | −20,660−100.0% | Sold out |
| Caption Management, LLC | 0 | $0 | 0.00% | −17,777−100.0% | Sold out |
| Atom Investors LP | 0 | $0 | 0.00% | −10,699−100.0% | Sold out |
| PDT Partners, LLC | 0 | $0 | 0.00% | −10,114−100.0% | Sold out |
| Lindbrook Capital, LLC | 0 | $0 | 0.00% | −1,006−100.0% | Sold out |